It will come as no surprise to the well-informed that if you are taking a 5-alpha-reductase inhibitor (a 5-ARI) like dutasteride or finasteride for benign prostatic hyperplasia (BPH), it significantly lowers your “normal” PSA level (to about half the actual value). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: 5-ARI, Diagnosis, dutasteride, finasteride, PSA, risk | 12 Comments »
Does adding dutasteride (Avodart) to abiraterone acetate (Zytiga) make any difference in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC)? There is no clear answer to this question from a small, Phase II, pilot study, the results of which have just been published in Clinical Cancer Research. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: abiraterone, castration-resistant, CRPC, dutasteride, metsatatic | 6 Comments »
Data from a randomized clinical trial have shown that there is more than one way to reduce the size of a man’s prostate (if such cytoreduction is needed) prior to treatment with permanent, radioactive pellets (permanent, low-dose brachytherapy) for localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: bicalutamide, brachytherapy, cytoreduction, dutasteride, randomized, trial | 6 Comments »
So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, dutasteride, IADT, IADT3, intermittent | 34 Comments »
Another study, just published in the British Medical Journal, appears to further debunk the idea that use of 5α-reductase inhibitors (5-ARIs) is associated with a significant increase in risk for development of high-grade prostate cancer. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5ARI, dutasteride, finasteride, Gleason, Prevention, risk | 2 Comments »
As is so often the case in medicine, data suggesting a positive finding from one study comes out at about the same time as data demonstrating exactly the opposite … and in prostate cancer this occurs all too frequently! … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: 5-ARI, benefit, dutasteride, finasteride, outcome, Prevention, risk | 39 Comments »
A poster at the Genitourinary Cancers Symposium yesterday will bring joy to Chuck Maack’s heart. It addressed the use of dutasteride in the off-therapy cycles of intermittent androgen deprivation therapy (ADT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, dutasteride, intermittent | 4 Comments »
New data from the ARTS study, reported in European Urology, suggests that dutateride may have a role in the treatment of men with biochemical failure after radical first-line therapy for prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ARTS, biochemical progression, dutasteride, outcome, second-line | 2 Comments »
According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical specimens in a small percentage of men diagnosed with high-risk disease. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: abiraterone, dutasteride, enzalutamide, leuprolide, MDV3100, neoadjuvant, pre-surgical | 6 Comments »
According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: dutasteride, low risk, Prevention, progression | 5 Comments »
The American Urological Association (AUA) has written to the U.S. Food & Drug Administration (FDA) seeking modification of the FDA’s recent guidance on the use of 5α-reductase inhibitors like dutasteride and finasteride in the management of urologic conditions. … READ MORE …
Filed under: Management, Prevention, Treatment | Tagged: 5-ARI, dutasteride, FDA, finasterine, guidance, safety | 1 Comment »
Yesterday the US Food & Drug Administration (FDA) updated its guidance on the use of 5α-reductase inhibitors with specific reference to the risk that use of these products may be able to induce high-grade (and therefore high-risk) prostate cancer in a small subset of men treated with these agents. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, FDA, finasteride, Prevention, risk | 4 Comments »
It is becoming increasingly clear that the prevention, treatment, and management of prostate cancer is at an intellectual as well as a practical, clinical crossroads. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: dutasteride, finasteride, Prevention, PSA, screening, supplement, testing, testosterone | 2 Comments »
Monique Roobol and her colleagues continue to mine data from the ERSPC and other major trials in a serious attempt to describe processes that would allow us to identify the vast majority of clinically significant prostate cancers while avoiding the unnecessary diagnosis and over-treatment of indolent disease. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, chemoprevention, combination, Diagnosis, dutasteride, risk, screening | 1 Comment »
Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
… READ MORE
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: adjuvant, ADT, bicalutamide, CyberKnife, dutasteride, intermittent, pomegranate, SBRT, screening | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 